Facing political pressure, Sanofi follows Eli Lilly and Novo Nordisk in slashing insulin prices
Publishing timestamp: 2023-03-16 17:32:51
Summary
Sanofi is planning to cut the U.S. price of its most popular insulin drug by 78% and cap monthly out-of-pocket costs at $35 for people who have private insurance starting next year. This comes after Eli Lilly and Novo Nordisk made similar sweeping price cuts earlier this month. The move is an attempt to head off government efforts to cap monthly costs by announcing its own steep price cuts for lifesaving hormone.
Sentiment: POSITIVE
Tickers: SNY, LLY, NOVO.B-DK, NVO, SAN-FR,
Keywords: joe biden, biotechnology, health care industry, business news, politics, pharmaceuticals, eli lilly and co, breaking news, novo nordisk a/s, biotech and pharmaceuticals, united states, sanofi sa, breaking news: business,